United States

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

24 Apr 2017
Change (% chg)

kr.0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Health Canada approves Otsuka and Lundbeck's REXULTI as a treatment for schizophrenia in adults
Friday, 17 Feb 2017 05:09pm EST 

H Lundbeck A/S : Health Canada approves Otsuka and Lundbeck's REXULTI(tm) (brexpiprazole) as a treatment for schizophrenia in adults .Lundbeck Canada - REXULTI will be co-marketed by two companies and is expected to become commercially available in Canada this spring.  Full Article

Lundbeck CEO says not concerned about Trump policies
Wednesday, 8 Feb 2017 05:06am EST 

Lundbeck CEO Kare Schultz says: Not concerned about the policies of U.S. President Donald Trump. . Doesn't think Trump policies can do anything of significance to affect Lundbeck. . No more layoffs planned as part of Lundbeck's cost cutting programme. . Certain to reach EBIT margin of 25 percent before 2020, says likely to reach the target in 2018. Further company coverage: [LUN.CO] (Reporting by Julie Astrid Thomsen, editing by Louise Heavens) ((julieastrid.thomsen@thomsonreuters.com;)).  Full Article

Lundbeck Q4 EBIT DKK 751 mln, above expectations
Wednesday, 8 Feb 2017 01:42am EST 

Lundbeck : Lundbeck continues to show solid revenue growth and strong improvement in profitability . Directors proposes to pay a dividend of 2.45 Danish crowns per share . For 2017, Lundbeck expects revenue of 16.3-17.1 billion crowns and EBIT of 3.4-3.8 billion crowns . Q4 revenue 4.17 billion crowns (Reuters poll 4.10 billion crowns) . Q4 EBIT 751 million crowns (Reuters poll 664 million crowns) .I am confident that we can deliver on our targets for coming years - Lundbeck’s President and CEO, Kare Schultz says in a statement.  Full Article

NNIT extends agreement with Lundbeck
Wednesday, 21 Dec 2016 04:18am EST 

Nnit A/S : Extends agreement with Lundbeck . Estimated total value of agreement consisting of three contracts will amount in high double-digit million Danish crown range .Agreement is effective as of January 1, 2017 and runs until end 2020, replacing existing agreement, which expires end 2017.  Full Article

H Lundbeck: FDA accepts sNDA for the expanded labeling of Abilify Maintena
Wednesday, 30 Nov 2016 09:02am EST 

H Lundbeck A/S : U.S. FDA accepts for review a supplemental new drug application to expand labeling of Abilify Maintena (Aripiprazole) for the treatment of Bipolar I disorder . If label expansion is approved, Abilify Maintena would offer prescribers a once-monthly long-acting injectable option in maintenance treatment of Bipolar I disorder in adults .Application seeks to expand Abilify Maintena label to include maintenance treatment for Bipolar I disorder.  Full Article

Lundbeck says alzheimer's drug late stage study fails
Thursday, 22 Sep 2016 12:01pm EDT 

H Lundbeck A/S : In first study, idalopirdine did not meet primary endpoint . Conclusions from first out of three phase 3 studies on idalopirdine in alzheimer's disease . Idalopirdine was safe and well tolerated .Two remaining studies, Starbeam and StarbrightII in phase 3 programme will continue as planned, data expected in first quarter of 2017.  Full Article

Lundbeck Q2 EBIT beats expectations; raises FY outlook
Wednesday, 24 Aug 2016 01:51am EDT 

H Lundbeck A/S : Q2 revenue 3.75 billion Danish crowns ($568.8 million) (Reuters poll 3.67 billion crowns) . Q2 EBIT 469 million crowns (Reuters poll 414 million crowns) . Now expects 2016 revenue of around 14.6 billion - 15.0 billion crowns compared to previously 14.2 billion - 14.6 billion crowns .2016 EBIT is expected to reach 1.5 billion - 1.7 billion crowns compared to 1.3 billion - 1.5 billion crowns.  Full Article

Lundbeck: Trintellix (vortioxetine) now available in US
Wednesday, 1 Jun 2016 10:29am EDT 

H Lundbeck A/S : Says Trintellix (vortioxetine) is now available in US . Says trade name for the vortioxetine product in US would be changed to Trintellix to avoid name confusion .Says formulation, indication and dosages of Trintellix remain the same as that of Brintellix.  Full Article

H Lundbeck Q1 EBIT 483 million; beats expectations
Wednesday, 11 May 2016 01:57am EDT 

H Lundbeck A/S : Q1 revenue 3.77 billion Danish crowns ($576.96 million) (Reuters poll 3.62 billion crowns) . Q1 EBIT 483 million crowns (Reuters poll 254 million crowns) . 2016 guidance raised based on solid sales performance and improved profitability .Now expects revenue of around 14.2-14.6 billion crowns and EBIT is expected to reach 1.3-1.5 billion crowns for 2016 compared to previously 13.8-14.2 billion crowns and 1.0-1.2 billion crowns, respectively.  Full Article

H Lundbeck A/S says Board elected Lars Rasmussen as Chairman
Thursday, 31 Mar 2016 07:32am EDT 

H Lundbeck A/S:Says Board of Directors has elected Lars Rasmussen as Chairman.  Full Article

More From Around the Web

BRIEF-Health Canada approves Otsuka and Lundbeck's REXULTI as a treatment for schizophrenia in adults

* Health Canada approves Otsuka and Lundbeck's REXULTI(tm) (brexpiprazole) as a treatment for schizophrenia in adults